Hims & Hers Health (NYSE:HIMS) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Hims & Hers Health (NYSE:HIMS) from a hold rating to a buy rating in a research report released on Sunday.

A number of other analysts have also recently commented on HIMS. Leerink Partners upped their price target on shares of Hims & Hers Health from $24.00 to $40.00 and gave the company a “market perform” rating in a research report on Tuesday, February 25th. Piper Sandler reaffirmed a “neutral” rating and set a $39.00 price target (up previously from $35.00) on shares of Hims & Hers Health in a research report on Tuesday, May 6th. Citigroup reaffirmed a “sell” rating and set a $30.00 price target (up previously from $25.00) on shares of Hims & Hers Health in a research report on Tuesday, May 6th. Needham & Company LLC upped their price target on shares of Hims & Hers Health from $61.00 to $65.00 and gave the company a “buy” rating in a research report on Wednesday, June 4th. Finally, TD Cowen cut shares of Hims & Hers Health from a “buy” rating to a “hold” rating and cut their price target for the company from $44.00 to $30.00 in a research report on Tuesday, April 29th. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, Hims & Hers Health has an average rating of “Hold” and an average target price of $38.00.

Hims & Hers Health Stock Down 1.0%

Shares of Hims & Hers Health stock opened at $59.17 on Friday. Hims & Hers Health has a twelve month low of $13.47 and a twelve month high of $72.98. The stock has a market cap of $13.24 billion, a price-to-earnings ratio of 85.75, a P/E/G ratio of 2.25 and a beta of 2.09. The company’s fifty day moving average is $46.36 and its 200 day moving average is $38.60.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings data on Monday, May 5th. The company reported $0.20 earnings per share for the quarter, topping the consensus estimate of $0.12 by $0.08. Hims & Hers Health had a net margin of 9.24% and a return on equity of 22.75%. The company had revenue of $586.01 million for the quarter, compared to analysts’ expectations of $535.21 million. During the same quarter in the previous year, the firm posted $0.05 earnings per share. Hims & Hers Health’s revenue for the quarter was up 110.7% on a year-over-year basis. As a group, equities analysts anticipate that Hims & Hers Health will post 0.29 earnings per share for the current fiscal year.

Insider Transactions at Hims & Hers Health

In related news, insider Soleil Boughton sold 3,236 shares of the company’s stock in a transaction dated Monday, March 31st. The shares were sold at an average price of $27.77, for a total value of $89,863.72. Following the sale, the insider now owns 170,285 shares in the company, valued at $4,728,814.45. This represents a 1.86% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Oluyemi Okupe sold 11,581 shares of the company’s stock in a transaction dated Wednesday, April 2nd. The stock was sold at an average price of $29.26, for a total transaction of $338,860.06. Following the completion of the sale, the chief financial officer now owns 124,104 shares in the company, valued at $3,631,283.04. This represents a 8.54% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 751,034 shares of company stock valued at $36,486,522 in the last 90 days. 17.71% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Hims & Hers Health

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. raised its holdings in shares of Hims & Hers Health by 11.1% in the 4th quarter. Vanguard Group Inc. now owns 20,257,116 shares of the company’s stock worth $489,817,000 after acquiring an additional 2,020,722 shares during the last quarter. Farallon Capital Management LLC increased its stake in Hims & Hers Health by 64,338.5% in the 4th quarter. Farallon Capital Management LLC now owns 8,377,000 shares of the company’s stock valued at $202,556,000 after buying an additional 8,364,000 shares during the last quarter. Renaissance Technologies LLC increased its stake in Hims & Hers Health by 29.0% in the 4th quarter. Renaissance Technologies LLC now owns 6,951,152 shares of the company’s stock valued at $168,079,000 after buying an additional 1,562,302 shares during the last quarter. Arrowstreet Capital Limited Partnership increased its stake in Hims & Hers Health by 192.0% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 6,304,202 shares of the company’s stock valued at $152,436,000 after buying an additional 4,145,305 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in Hims & Hers Health by 0.9% in the 4th quarter. Geode Capital Management LLC now owns 4,329,996 shares of the company’s stock valued at $104,724,000 after buying an additional 40,447 shares during the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.